<?npg-journal-abbreviation?>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NPGSJ//DTD full length article DTD version 7.0 XML//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ajarticle_v7_x.dtd?>
<?SourceDTD.Version 7.0?>
<?ConverterInfo.XSLTName naturesa2nlmx2.xsl?>
<?ConverterInfo.Version 2?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Cell Death Differ</journal-id>
    <journal-id journal-id-type="iso-abbrev">Cell Death Differ</journal-id>
    <journal-title-group>
      <journal-title>Cell Death and Differentiation</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1350-9047</issn>
    <issn pub-type="epub">1476-5403</issn>
    <publisher>
      <publisher-name>Nature Publishing Group</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">3554342</article-id>
    <article-id pub-id-type="pii">cdd2012137</article-id>
    <article-id pub-id-type="doi">10.1038/cdd.2012.137</article-id>
    <article-id pub-id-type="pmid">23175189</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Correspondence</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Antonov</surname>
          <given-names>A V</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">1</xref>
        <xref ref-type="corresp" rid="caf1">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Knight</surname>
          <given-names>R A</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Melino</surname>
          <given-names>G</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">1</xref>
        <xref ref-type="aff" rid="aff2">2</xref>
        <xref ref-type="aff" rid="aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Barlev</surname>
          <given-names>N A</given-names>
        </name>
        <xref ref-type="aff" rid="aff3">3</xref>
        <xref ref-type="aff" rid="aff4">4</xref>
        <xref ref-type="aff" rid="aff5">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tsvetkov</surname>
          <given-names>P O</given-names>
        </name>
        <xref ref-type="aff" rid="aff6">6</xref>
      </contrib>
      <aff id="aff1"><label>1</label><institution>Medical Research Council Toxicology Unit, Leicester University</institution>, Leicester LE1 9HN, <country>UK</country></aff>
      <aff id="aff2"><label>2</label><institution>Department of Experimental Medicine and Surgery, University of Rome ‘Tor Vergata'</institution>, Rome 00133, <country>Italy</country></aff>
      <aff id="aff3"><label>3</label><institution>Saint-Petersburg State Institute of Technology</institution>, Moscovskii avenue 26, Saint-Petersburg 190013, <country>Russia</country></aff>
      <aff id="aff4"><label>4</label><institution>Department of Biochemistry, University of Leicester</institution>, Leicester LE1 9HN, <country>UK</country></aff>
      <aff id="aff5"><label>5</label><institution>Institute of Cytology</institution>, 194064 Saint-Petersburg, <country>Russia</country></aff>
      <aff id="aff6"><label>6</label><institution>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences</institution>, Vavilov Street 32, Moscow 119991, <country>Russia</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="caf1"><label>*</label><institution>Medical Research Council Toxicology Unit</institution>, Hodgkin Building, Lancaster Road, PO Box 138, Leicester LE1 9HN, <country>UK</country>. Tel: +44 (0) 116 252 5562; Fax: +44 (0)116 252 5616; E-mail: <email>aa668@le.ac.uk</email></corresp>
    </author-notes>
    <pub-date pub-type="ppub">
      <month>02</month>
      <year>2013</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>11</month>
      <year>2012</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>1</day>
      <month>2</month>
      <year>2013</year>
    </pub-date>
    <volume>20</volume>
    <issue>2</issue>
    <fpage>367</fpage>
    <lpage>367</lpage>
    <permissions>
      <copyright-statement>Copyright © 2013 Macmillan Publishers Limited</copyright-statement>
      <copyright-year>2013</copyright-year>
      <copyright-holder>Macmillan Publishers Limited</copyright-holder>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
        <!--author-paid-->
        <license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/</license-p>
      </license>
    </permissions>
  </article-meta>
</front>
<body>
  <p><italic>Dear Editor</italic>,</p>
  <p>Although multiple clinical studies have correlated microRNA (miR) expression profiles with clinical outcome in cancer patients,<sup><xref ref-type="bibr" rid="bib1">1</xref></sup> most data sets in the public domain have a complex interface, which is difficult to use by a non-specialist public and requires advanced informatics and statistical skills. Here, we present MIRUMIR, a tool which performs survival analyses and draws Kaplan–Meier (KM) plots for submitted ‘microRNA' across several available data sets, which cover more than 800 patients. A robust statistical procedure is implemented to account for multiple testing. MIRUMIR is incorporated into BioProfiling.de, analytical portal for high-throughput cell biology,<sup><xref ref-type="bibr" rid="bib2">2</xref></sup> and is freely available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.bioprofiling.de/MIRUMIR">http://www.bioprofiling.de/MIRUMIR</ext-link>.</p>
  <p>Similar tools were developed recently to assess the relationship between expression levels of various genes with clinical outcome.<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> KM plots provides meta-analyses by combining multiple gene expression data sets. MIRUMIR is the first tool specifically designed for miRs. Unlike KM plots, MIRUMIR screens publicly available miR expression data sets one by one implementing robust statistical procedures to adjust <italic>P</italic>-value for multiple testing. Data sets have been downloaded from the GEO omnibus repository.<sup><xref ref-type="bibr" rid="bib4">4</xref></sup> To be selected the data set must be a clinical data set (patients) and have at least 50 profiled samples annotated with survival information. Currently, MIRUMIR comprises nine data sets covering breast, prostate and ovarian cancers that we plan to expand shortly.</p>
  <p>MIRUMIR exploits rank information from expression data sets. For each available data set samples are grouped with respect to expression rank of the user specified miR. The ‘low expression' and ‘high expression' groups are those where expression rank of miR is less or more than average expression rank across the data set, respectively. This separation of patients into ‘low' and ‘high' groups along with survival information is next used to find any statistical differences in survival outcome. The R statistical package is used to perform survival analyses<sup><xref ref-type="bibr" rid="bib5">5</xref></sup> and to draw KM plots, see <xref ref-type="supplementary-material" rid="sup1">Supplementary Material</xref> for MIRUMIR practical analyses of several miR examples. There are sources of multiple testing that should be accounted for. Obviously, the miR hypothesis is tested across each available data set. Therefore, the final number of tested hypotheses is equal to the number of screened expression data sets. In addition, for some data sets, the miR can be mapped to several probes, which means several hypotheses tested for one data set. False discovery rate<sup><xref ref-type="bibr" rid="bib6">6</xref></sup> control procedure is implemented to automatically adjust <italic>P</italic>-values for multiple testing.</p>
  <p>In summary, MIRUMIR supports the need of biomedical researchers to estimate the power of miR to serve as potential biomarker to predict survival of cancer patients. MIRUMIR provides such analyses based on several publicly available clinical miR data sets annotated with patient survival information. To our knowledge this is a first simple tool of this kind and, as shown by several examples (see <xref ref-type="supplementary-material" rid="sup1">Supplementary Materials</xref>), MIRUMIR is ideal for fast validation of the clinical relevance of a selected miR.</p>
</body>
<back>
  <ack>
    <p>This work was supported by the UK Medical Research Council (MRC) and funding from RFBS (10-04-01234), MCB RAS, Russian Federal grants 16.740.11.036 (to NB) and 11.G34.31.0069 (to GM).</p>
  </ack>
  <fn-group>
    <fn>
      <p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)</p>
    </fn>
  </fn-group>
  <notes>
    <p>The authors declare no conflict of interest.</p>
  </notes>
  <ref-list>
    <ref id="bib1">
      <mixed-citation publication-type="other">
        <person-group person-group-type="author">
          <name>
            <surname>Lovat</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Valeri</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Croce</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <source>Semin Oncol</source>
        <year>2011</year>
        <volume>38</volume>
        <fpage>724</fpage>
        <lpage>733</lpage>
        <pub-id pub-id-type="pmid">22082758</pub-id>
      </mixed-citation>
    </ref>
    <ref id="bib2">
      <mixed-citation publication-type="other">
        <person-group person-group-type="author">
          <name>
            <surname>Antonov</surname>
            <given-names>AV</given-names>
          </name>
        </person-group>
        <source>Nucleic Acids Res</source>
        <year>2011</year>
        <volume>39</volume>
        <fpage>W323</fpage>
        <lpage>W327</lpage>
        <pub-id pub-id-type="pmid">21609949</pub-id>
      </mixed-citation>
    </ref>
    <ref id="bib3">
      <mixed-citation publication-type="other">
        <person-group person-group-type="author">
          <name>
            <surname>Gyorffy</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <source>Breast Cancer Res Treat</source>
        <year>2010</year>
        <volume>123</volume>
        <fpage>725</fpage>
        <lpage>731</lpage>
        <pub-id pub-id-type="pmid">20020197</pub-id>
      </mixed-citation>
    </ref>
    <ref id="bib4">
      <mixed-citation publication-type="other">
        <person-group person-group-type="author">
          <name>
            <surname>Barrett</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <source>Nucleic Acids Res</source>
        <year>2009</year>
        <volume>37</volume>
        <fpage>D885</fpage>
        <lpage>D890</lpage>
        <pub-id pub-id-type="pmid">18940857</pub-id>
      </mixed-citation>
    </ref>
    <ref id="bib5">
      <mixed-citation publication-type="other">
        <person-group person-group-type="author">
          <name>
            <surname>Harrington</surname>
          </name>
          <name>
            <surname>Fleming</surname>
          </name>
        </person-group>
        <source>Biometrika</source>
        <year>1982</year>
        <volume>69</volume>
        <fpage>553</fpage>
        <lpage>566</lpage>
      </mixed-citation>
    </ref>
    <ref id="bib6">
      <mixed-citation publication-type="other">
        <person-group person-group-type="author">
          <name>
            <surname>Hochberg</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Benjamini</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <source>Stat Med</source>
        <year>1990</year>
        <volume>9</volume>
        <fpage>811</fpage>
        <lpage>818</lpage>
        <pub-id pub-id-type="pmid">2218183</pub-id>
      </mixed-citation>
    </ref>
  </ref-list>
  <sec sec-type="supplementary-material" id="sup1">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="xob1">
      <label>Supplementary Information</label>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="application" mime-subtype="msword" xlink:href="cdd2012137x1.doc">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</back>
